←
Graves' Disease & Thyroid Foundation8,514 posts
Graves' Disease & Thyroid Foundation avatar

Graves' Disease & Thyroid Foundation

@GDATF

The Graves’ Disease & Thyroid Foundation provides educational and support services for patients with Graves’ disease, thyroid eye disease & related disorders.

◷ Joined October 2011▧ 385 Photos and videos
Viridian Therapeutics, Inc. avatar
⟳ Graves' Disease & Thyroid Foundation retweeted
Viridian Therapeutics, Inc.@ViridianThera·Nov 9

Today kicks off #TEDAwarenessWeek! We’re proud to be a 2026 sponsor & work with organizations like @PBA_savingsight & the broader TED community to drive progress forward for people living with Thyroid Eye Disease. Follow along for TED-related info & share to help raise awareness:

It's the 7th Annual Thyroid Eye Disease (TED) Week at @PBA_savingsight! This week, we're sharing helpful resources to raise awareness, provide education, and connect individuals with TED and their care partners to support services. Fact sheets, webpages, and expert and patient videos are available from Prevent Blindness with information on risk factors, symptoms, treatment options and more. Visit our website at: preventblindness.org/thyroid… TED Week is supported by funding from Platinum sponsors @Amgen and @ViridianThera. #TEDWeek

U.S. FDA avatar
⟳ Graves' Disease & Thyroid Foundation retweeted
U.S. FDA@FDA·Nov 9

Today, we are informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of GLP-1 RA medications. NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. Symptoms of NAION include sudden, painless vision loss in one eye that patients may notice upon waking: visual defects such as blind spots, distortion of colors, blurriness, or tunnel vision. Patients should contact their health care professional right away if they have any of these symptoms. fda.gov/drugs/drug-safety-co…

Post attachment
Graves' Disease & Thyroid Foundation avatar
Graves' Disease & Thyroid Foundation@GDATF·Oct 19

Science can move "gradually, then suddenly"! Just days after we attended the ASOPRS Fall Symposium - which included talks on the SatraGO-1 and SatraGO-2 trials - the FDA has approved Enspryng as the first subcutaneous treatment for thyroid eye disease. optometryadvisor.com/news/en…

Graves' Disease & Thyroid Foundation avatar
Graves' Disease & Thyroid Foundation@GDATF·Sep 13

REMINDER: Survey closes at the end of the day on Tuesday! Get started here: survey.us.confirmit.com/wix/…

Our Graves' survey for USA-based patients has been extended to Sep. 15th - we'd be honored if you would participate! Check out this video from Exec Director Kimberly Dorris for survey tips & insight on how we use survey data - or jump into the survey here: bit.ly/4h8RRHh

2:29
Graves' Disease & Thyroid Foundation avatar
Graves' Disease & Thyroid Foundation@GDATF·Sep 3

Our Graves' survey for USA-based patients has been extended to Sep. 15th - we'd be honored if you would participate! Check out this video from Exec Director Kimberly Dorris for survey tips & insight on how we use survey data - or jump into the survey here: bit.ly/4h8RRHh

2:29